ATE345115T1 - Zusammensetzungen zur behandlung von chlamydiale assozierten krankheiten - Google Patents

Zusammensetzungen zur behandlung von chlamydiale assozierten krankheiten

Info

Publication number
ATE345115T1
ATE345115T1 AT99928901T AT99928901T ATE345115T1 AT E345115 T1 ATE345115 T1 AT E345115T1 AT 99928901 T AT99928901 T AT 99928901T AT 99928901 T AT99928901 T AT 99928901T AT E345115 T1 ATE345115 T1 AT E345115T1
Authority
AT
Austria
Prior art keywords
treatment
compositions
chlamydial
associated diseases
trimoxazole
Prior art date
Application number
AT99928901T
Other languages
German (de)
English (en)
Inventor
Karl William Baumgart
Highway Pacific
Thomas Julius Borody
Original Assignee
Karl William Baumgart
Borody Thomas J
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karl William Baumgart, Borody Thomas J filed Critical Karl William Baumgart
Application granted granted Critical
Publication of ATE345115T1 publication Critical patent/ATE345115T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT99928901T 1998-06-30 1999-06-30 Zusammensetzungen zur behandlung von chlamydiale assozierten krankheiten ATE345115T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPP4376A AUPP437698A0 (en) 1998-06-30 1998-06-30 Methods for treatment of coronary, carotid and other vascular disease

Publications (1)

Publication Number Publication Date
ATE345115T1 true ATE345115T1 (de) 2006-12-15

Family

ID=3808619

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99928901T ATE345115T1 (de) 1998-06-30 1999-06-30 Zusammensetzungen zur behandlung von chlamydiale assozierten krankheiten

Country Status (10)

Country Link
US (1) US6475518B1 (cg-RX-API-DMAC7.html)
EP (2) EP1754472B1 (cg-RX-API-DMAC7.html)
JP (3) JP4651816B2 (cg-RX-API-DMAC7.html)
AT (1) ATE345115T1 (cg-RX-API-DMAC7.html)
AU (2) AUPP437698A0 (cg-RX-API-DMAC7.html)
CA (2) CA2684402C (cg-RX-API-DMAC7.html)
DE (1) DE69934010T2 (cg-RX-API-DMAC7.html)
ES (2) ES2278449T3 (cg-RX-API-DMAC7.html)
NZ (1) NZ509504A (cg-RX-API-DMAC7.html)
WO (1) WO2000001378A1 (cg-RX-API-DMAC7.html)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6710033B1 (en) 1996-08-14 2004-03-23 Vanderbilt University Methods and treatment of multiple sclerosis
US6258532B1 (en) 1997-08-14 2001-07-10 Vanderbilt University Methods for in vitro susceptibility testing of chlamydia
US6890526B2 (en) 1997-05-06 2005-05-10 Vanderbilt University Methods and reagents for the treatment of multiple sclerosis
US6756369B2 (en) * 1997-05-06 2004-06-29 Vanderbilt University Diagnosis and management of infection caused by Chlamydia
WO2000057187A2 (en) * 1999-03-19 2000-09-28 Vanderbilt University Diagnosis and treatment of multiple sclerosis
US6991807B2 (en) * 2000-02-24 2006-01-31 Advancis Pharmaceutical, Corp. Antibiotic composition
EP1267765A4 (en) * 2000-02-24 2008-12-24 Middlebrook Pharmaceuticals In ANTIBIOTIC AND MUSHROOM AGENTS
US6514529B2 (en) 2000-03-22 2003-02-04 Pharmacia & Upjohn Company Oxazolidinone tablet formulation
YU69802A (sh) * 2000-03-22 2005-11-28 Pharmacia & Upjohn Company Formulacija oksazolidinon tablete
IT1318459B1 (it) * 2000-04-11 2003-08-25 Zambon Spa Uso del tiamfenicolo e di suoi derivati per la preparazione dicomposizioni farmaceutiche utili per il trattamento di infezioni da
US20020169112A1 (en) * 2001-05-08 2002-11-14 Luc Montagnier Combined treatments and methods for treatment of mycoplasma and mycoplasma-like organism infections
EP1262185A1 (en) * 2001-05-30 2002-12-04 New Pharma Research Sweden AB Synergistic antibiotic compositions
WO2003004098A1 (en) * 2001-07-06 2003-01-16 Sucampo Ag Composition for topical administration comprising an interleukin-2 inhibitor and an antimicrobial agent
UA79952C2 (en) * 2001-12-10 2007-08-10 Kabulesh Mafatlal Khamar MYCOBACTERIUM w APPLICATIONS FOR CANCER TREATMENT
AUPS017702A0 (en) * 2002-01-25 2002-02-14 Atopic Pty Ltd Methods and compositions for the treatment of asthma and related disorders
AUPS088702A0 (en) * 2002-03-04 2002-03-28 Borody, Thomas Julius Electrolyte purgative
JP2005526059A (ja) * 2002-03-07 2005-09-02 アドバンシス ファーマスーティカル コーポレイション 抗生物質組成物
WO2003099217A2 (en) * 2002-05-23 2003-12-04 Activbiotics, Inc. Methods of treating bacterial infections and diseases associated therewith
US20090149453A1 (en) * 2002-05-23 2009-06-11 Activbiotics Pharma Llc Methods and compositions for treating bacterial infections and diseases associated therewith
US20040077533A1 (en) * 2002-05-23 2004-04-22 Sayada Chalom B. Methods and compositions for treating bacterial infections and diseases associated therewith
US7108992B2 (en) * 2002-11-27 2006-09-19 St. Jude Children's Research Hospital ATM kinase compositions and methods
US6916627B2 (en) * 2002-11-27 2005-07-12 St. Jude Children's Research Hospital ATM kinase compositions and methods
US20040176404A1 (en) * 2002-12-12 2004-09-09 Sayada Chalom B. Methods and reagents for treating or preventing atherosclerosis and diseases associated therewith
US20040126414A1 (en) * 2002-12-12 2004-07-01 Michaelis Arthur F. Methods and compositions for treating and preventing ear infections
US20050013835A1 (en) * 2003-07-15 2005-01-20 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
RU2254123C2 (ru) * 2003-08-11 2005-06-20 Государственное научное учреждение Институт экспериментальной ветеринарии Сибири и Дальнего Востока Сибирского отделения Россельхозакадемии (ГНУ ИЭВСиДВ СО РАСХН) Препарат для лечения гемобартонеллеза кошек и способ его применения
WO2005027961A2 (en) * 2003-09-23 2005-03-31 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Chlamydia pmpd autotransporter and its role as adhesin
WO2005074908A1 (en) 2004-02-06 2005-08-18 Borody, Thomas, Julius Use of aminosalicylates in diarrhoea-predominent irritable bowel syndrome
KR20130028807A (ko) * 2004-05-28 2013-03-19 샐릭스 파마슈티컬스 인코포레이티드 방사선 유발성 장염의 예방, 치료 및 개선 방법
EA016776B9 (ru) 2004-09-30 2012-11-30 Ковалон Текнолоджиз Инк. Неадгезивные эластичные желатиновые матрицы
JPWO2006057429A1 (ja) * 2004-11-24 2008-06-05 ナノキャリア株式会社 ブロックコポリマーのモーフォロジーの変化方法
CA2620091A1 (en) * 2005-08-24 2007-03-01 Salix Pharmaceuticals, Inc. Balsalazide formulations and manufacture and use thereof
US8921344B2 (en) * 2006-11-03 2014-12-30 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
US7452872B2 (en) 2005-08-24 2008-11-18 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
FR2891744B1 (fr) * 2005-10-06 2009-10-09 France Etat Armement Application a la chimioprophylaxie du paludisme d'une association de chloroquine et de doxycycline
WO2009015214A2 (en) * 2007-07-24 2009-01-29 Wayne State University Nanoparticles for imaging and treating chlamydial infection
EP2365802B1 (en) 2008-11-11 2017-08-02 The Board of Regents,The University of Texas System Microcapsules of rapamycin and use for treating cancer
US8999360B2 (en) * 2009-10-22 2015-04-07 Thomas Julius Borody Compositions and methods for treating extracellular parasitic infections
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
WO2011137103A1 (en) 2010-04-26 2011-11-03 Salix Pharmaceuticals, Ltd. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives for the treatment of males
CN103338768B (zh) 2010-12-13 2019-04-19 萨利克斯药品有限公司 胃和结肠的配制剂及其制备和使用方法
CA2843696C (en) * 2011-08-16 2019-09-24 Purac Biochem B.V. Recovery of carboxylic acid from their magnesium salts by precipitation using hydrochloric acid, useful for fermentation broth work-up
ES2717282T3 (es) 2012-07-27 2019-06-20 Redhill Biopharma Ltd Formulaciones y métodos para fabricar formulaciones para su uso en la evacuación colónica
EP2968281B1 (en) 2013-03-13 2020-08-05 The Board of Regents of The University of Texas System Mtor inhibitors for prevention of intestinal polyp growth
AU2014373683B2 (en) 2013-12-31 2020-05-07 Rapamycin Holdings, Llc Oral rapamycin nanoparticle preparations and use
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
KR20180058716A (ko) * 2015-10-06 2018-06-01 레드힐 바이오파마 엘티디 암을 치료하기 위한 병용 요법
US11229657B2 (en) 2017-04-21 2022-01-25 Lunella Biotech, Inc. Targeting hypoxic cancer stem cells (CSCs) with doxycycline: implications for improving anti-angiogenic therapy
EP3612187B1 (en) 2017-04-21 2022-04-13 Lunella Biotech, Inc. Vitamin c and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (cscs)
WO2018213764A1 (en) 2017-05-19 2018-11-22 Lunella Biotech, Inc. Companion diagnostics for mitochondrial inhibitors
JP6938682B2 (ja) 2017-05-19 2021-09-22 ルネラ・バイオテック・インコーポレーテッド アンチミトシン:癌幹細胞を根絶するためのミトコンドリア生合成の標的阻害薬
US11667639B2 (en) 2017-06-26 2023-06-06 Lunella Biotech, Inc. Mitoketoscins: mitochondrial-based therapeutics targeting ketone metabolism in cancer cells
WO2019148249A1 (en) * 2018-02-01 2019-08-08 Centre For Digestive Diseases Compositions for treating infective arterial diseases and related conditions
RU2684728C1 (ru) * 2018-05-21 2019-04-12 федеральное государственное бюджетное образовательное учреждение высшего образования "Ставропольский государственный аграрный университет" Препарат на основе пчелиного маточного молочка для лечения мелких домашних животных при гемобартонеллезе
CA3180390A1 (en) * 2020-03-27 2021-09-30 Fergus MANFORD Compositions for the treatment of a respiratory condition

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US588550A (en) 1897-08-24 Alarm-clock
GB1463550A (en) 1974-08-06 1977-02-02 Bodrero G Pharmaceutical composition
GB2189699A (en) 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
FI883067A7 (fi) * 1988-06-27 1989-12-28 Labsystems Oy Foerfarande foer behandling av koronarkaerlsjukdom.
US5914132A (en) 1993-02-26 1999-06-22 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
GB9416600D0 (en) 1994-08-17 1994-10-12 Smithkline Beecham Plc Pharmaceutical formulation
US5624704A (en) 1995-04-24 1997-04-29 Baylor College Of Medicine Antimicrobial impregnated catheters and other medical implants and method for impregnating catheters and other medical implants with an antimicrobial agent
US6080757A (en) * 1996-06-06 2000-06-27 Pfizer Inc Antibiotic quinolones and derivatives
US6838552B1 (en) * 1997-08-14 2005-01-04 Vanderbilt University Diagnosis and management of infection caused by Chlamydia
US5811121A (en) 1997-01-29 1998-09-22 Eastman Chemical Company PH-sensitive coatings based on cellulose acetoacetate
JP2002512622A (ja) * 1997-05-06 2002-04-23 バンダービルト ユニバーシティー クラミジアにより引き起こされる感染の診断および管理のための抗クラミジア剤の組成物

Also Published As

Publication number Publication date
NZ509504A (en) 2004-04-30
EP1754472A2 (en) 2007-02-21
US6475518B1 (en) 2002-11-05
JP2013147504A (ja) 2013-08-01
CA2684402A1 (en) 2000-01-13
EP1093363A1 (en) 2001-04-25
HK1037864A1 (en) 2002-02-22
CA2684402C (en) 2012-10-30
EP1093363A4 (en) 2003-09-24
CA2336593A1 (en) 2000-01-13
EP1754472B1 (en) 2014-07-23
ES2514469T3 (es) 2014-10-28
WO2000001378A1 (en) 2000-01-13
AU757293B2 (en) 2003-02-13
DE69934010T2 (de) 2007-06-21
AUPP437698A0 (en) 1998-07-23
ES2278449T3 (es) 2007-08-01
JP2002519374A (ja) 2002-07-02
CA2336593C (en) 2010-06-29
DE69934010D1 (de) 2006-12-28
EP1093363B1 (en) 2006-11-15
EP1754472A3 (en) 2009-08-26
JP4651816B2 (ja) 2011-03-16
JP2010174030A (ja) 2010-08-12
AU4591999A (en) 2000-01-24
JP5335726B2 (ja) 2013-11-06

Similar Documents

Publication Publication Date Title
ATE345115T1 (de) Zusammensetzungen zur behandlung von chlamydiale assozierten krankheiten
DE60117043D1 (de) Behandlung von mukositis
DE69529670D1 (de) Oxazolidinon derivate und diese enthaltende pharmazeutische zusammensetzungen
ATE335499T1 (de) Zusammensetzungen zur behandlung von staphylococcus aureus infektionen
ATE279942T1 (de) Mehrwertige impstoffzusammensetzung mit gemischten trägern
HUP9901144A2 (hu) Hatóanyagként klopidogrel és egy antitrombotikum új kombinációját tartalmazó gyógyszerkészítmények
CY1109695T1 (el) Μικροοργανισμοι αποδομησης οξαλικου ή ενζυμα αποδομησης οξαλικου για την προληψη παθησης σχετιζομενης με οξαλικο
EP0932613A4 (en) EXPRESSION BLOCKING OF VIRULENT FACTORS IN S. AUREUS
DE60041753D1 (de) Arzneimittel zur behandlung von c. pneumoniae infektionen
DE69825128D1 (de) Verwendung von azithromycin zur topischen behandlung von augeninfektionen
DE69631381T2 (de) Therapeutische und diagnostische agenzien zur behandlung mikrobieller infektionen
PT775745E (pt) Aptameros inibidores de catepsina g
DE69914911D1 (de) Pharmazeutische präparate zur bekämpfung oder prophylaxe von mikroorganismen infizierten oberflächen
DK0824539T3 (da) Dialkyltiacumicin-forbindelser
ID25478A (id) Agonis 5-ht1f
ATE260097T1 (de) Hopfensäuren zur hemmung von staphylococcus aureus
DE60011601D1 (de) Rekombinantes sp-a zur behandlung und vorbeugung von pulmonaren infektionen und entzündungen
EP1496742A4 (en) USE OF NON-ANTIBIBTERIAL TETRAZYKLIN ANALOGUES AND ITS FORMULATIONS FOR THE TREATMENT OF BACTERIAL EXOTOXINES
DE69935662D1 (de) Mittel zur prävention/behandlung entzündlicher darmerkrankungen
BG101145A (bg) Използване на /s/-аденозил-l-метионин /саме/ i неговите физиологично съвместими соли за лечение нареперфузионно увреждане, причинено от временна фокална исхемиа
ATE196424T1 (de) Methode und zusammensetzung zur behandlung von herpes ähnlichen krankheiten
ATE212229T1 (de) Bismut und antimikrobielle mittel enthaltende zusammensetzung zur verhütung und behandlung gastrointestinaler beschwerden
WO1998014567A3 (en) Methods and compositions for inhibiting bacterial growth
ATE298235T1 (de) Heilmittel und prophylaxe von störungen der intestinalen schleimhäute
ATE263556T1 (de) Phenylessigsäure enthaltende zusammensetzungen zur behandlung und vorbeugung der atherosklerose und der restenose

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties